BioSpace News Archive

“We are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of U.S. citizens and others worldwide,” said Stanley C. Erck, president and chief executive officer of Novavax.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.

This year’s event, which kicks off June 8, will have a different look as an entirely digital conference.

UK-based AstraZeneca and the University of Oxford have partnered on the global development and distribution of Oxford’s COVID-19 vaccine, AZD1222.

With the close of the fund, Atlas Venture said it will continue to advance its mission of “doing well by doing good” and building biotech companies that will deliver high-impact therapies to patients.

Daiichi Sankyo announced on May 28 that it had entered an agreement with Syneos Health to form a coalition dedicated to bringing new cancer therapies to patients in a safe and effective manner.

Inovio’s development issues for its vaccine candidate have become mired in a conflict with the contract manufacturing organization it has worked with on previous projects.

The next two weeks are busy ones for the U.S. Food and Drug Administration (FDA). Here’s a look at PDUFA dates for this period.

As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, announced that, following discussions with the U.S. Food and Drug Administration, a clinical hold was issued for the clinical trial AAVance, a global Phase 2/3 clinical trial of LYS-SAF302, a gene therapy for the treatment of Mucopolysaccharidosis Type IIIA